A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

European Journal of Cancer

Volumn 49, Issue 5, 2013, Pages 999-1008

  Choo, S P ^a   Chowbay, B ^a   Ng, Q S ^a   Thng, C H ^a   Lim, Cindy ^a   Hartono, S ^b   Koh, T S ^b   Huynh, H ^c   Poon, D ^a   Ang, M K ^a   Chang, S ^d   Toh, H C ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Bevacizumab; DCE CT imaging' sirolimus; Hepatocellular carcinoma; Rapamycin

Indexed keywords

BEVACIZUMAB; RAPAMYCIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD FLOW; BLOOD FLOW VELOCITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SIROLIMUS; TREATMENT OUTCOME;

EID: 84874941374     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.008     Document Type: Article

References (24)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. R.S. Finn, and A.X. Zhu Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab Expert Rev Anticancer Ther 9 4 2009 503 509
3. V. Bioge, D. Malka, and A. Bourredjem Efficacy, safety and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma Oncologist 17 8 2012 1063 1072
4. F. Sahin, R. Kannangai, O. Adegbola, J. Wang, G. Su, and M. Torbenson MTOR and P70S6 kinase expression in primary liver neoplasms Clin Cancer Res 10 2004 8421 8425
5. W. Sieghart, T. Fuereder, and K. Schmid Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation Transplantation 83 2007 425 432
6. M. Rizell, M. Andersson, C. Cahlin, L. Hafström, M. Olausson, and P. Lindnér Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer Int J Clin Oncol 13 2008 66 70
7. T. Decaens, A. Luciani, and E. Itti A Phase 2 study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma Dig Liver Dis 44 7 2012 610 616
8. H. Huynh, P. Chow, and N. Palanisamy Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma J Hepatol 49 2008 52 60
9. L.C. Ong, I.C. Song, and Y. Jin Effective inhibition of xenografts of hepatocellular carcinoma by rapamycin and bevacizumab in an intrahepatic model Mol Imag Biol 11 2009 334 342
10. H. Huynh, K.C. Soo, P.K. Chow, L. Panasci, and E. Tran Xenografts of human hepatocellular carcinoma: a useful model for testing drugs Clin Cancer Res 12 14 Pt 1 2006 4306 4314
11. R. Lencioni, and J.M. Llovet Modified RECIST assessment for hepatocellular carcinoma Semin Liver Dis 30 1 2010 52 60
12. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
13. Q.S. Ng, C.H. Thng, and W.T. Lim Dynamic contrast-enhanced computed tomography in metastatic nasopharyngeal carcinoma: reproducibility analysis and observer variability of the distributed parameter model Invest Radiol 47 1 2012 5 10
14. T.S. Koh, C.H. Thng, and P.S. Lee Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model Radiology 249 2008 307 320
15. M. Guba, G.E. Koehl, and E. Neppl Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer Transpl Int 18 1 2005 89 94
16. A. Jimeno, M.A. Rudek, and P. Kulesza Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumours J Clin Oncol 26 2008 4172 4179
17. E.E. Cohen, M.R. Sharma, and L. Janisch A phase I study of sirolimus and bevacizumab in patients with advanced malignancies Eur J Cancer 47 10 2011 1484 1489
18. J.P. Thomas, R.Z. Arzoomanian, and D. Alberti Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 21 2003 223 231
19. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
20. H.Q. Xiong, R. Herbst, and S.C. Faria A phase I surrogate endpoint study of SU6668 in patients with solid tumors Invest New Drugs 22 2004 459 466
21. Q.S. Ng, V. Goh, and J. Milner Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study Lancet Oncol 8 2007 111 118
22. M.R. Meijerink, H. van Cruijsen, and K. Hoekman The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients Eur Radiol 17 2007 1700 1713
23. C.I. Wong, T.S. Koh, and R. Soo Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies J Clin Oncol 27 28 2009 4718 4726
24. H.A. Lane, J.M. Wood, and P.M.J. McSheehy MTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor Clin Cancer Res 15 2009 1612 1622